Summary: Elevated cholesterol levels are one of the main factors in the development of cardiovascular diseases caused by atherosclerosis. It has been proved a linear relationship between the height of LDL-C and cardiovascular training. And all 1 umol/l (about 38 mg/dl) LDL-C reductions make up 20‒25% of the cardiovascular increases. This is especially important if you wish to have preparations and tools to support your cardiovascular risk. In these patients, initiate cholesterol-lowering therapy as soon as possible. It should also be noted that the degree of cholesterol reduction in these patients must be significant. Therefore, more and more often, PCSK9 inhibitors join the therapy with statin and ezetimibe. Evolocumab and alirocumab are available in Poland.